Analysts Set Mirati Therapeutics Inc (NASDAQ:MRTX) Target Price at $92.38

Share on StockTwits

Mirati Therapeutics Inc (NASDAQ:MRTX) has earned a consensus recommendation of “Buy” from the seventeen brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $92.38.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Mirati Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 8th. BidaskClub raised shares of Mirati Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 11th. Cowen reaffirmed a “buy” rating on shares of Mirati Therapeutics in a report on Tuesday, June 4th. Barclays increased their price objective on shares of Mirati Therapeutics from $85.00 to $123.00 and gave the company an “overweight” rating in a report on Wednesday, June 5th. Finally, Guggenheim lowered shares of Mirati Therapeutics from a “buy” rating to a “neutral” rating and set a $95.56 price objective for the company. in a report on Friday, June 7th.

Mirati Therapeutics stock traded up $6.16 during midday trading on Monday, hitting $100.42. The stock had a trading volume of 518,936 shares, compared to its average volume of 740,305. The stock has a fifty day moving average of $75.61. The stock has a market capitalization of $3.40 billion, a P/E ratio of -31.48 and a beta of 1.68. Mirati Therapeutics has a 52-week low of $28.50 and a 52-week high of $102.59.

Mirati Therapeutics (NASDAQ:MRTX) last released its earnings results on Monday, April 29th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.20). The company had revenue of $1.24 million for the quarter. On average, equities research analysts forecast that Mirati Therapeutics will post -5 EPS for the current fiscal year.

In related news, major shareholder Venbio Select Advisor Llc sold 23,781 shares of the firm’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $72.80, for a total value of $1,731,256.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bruce L. A. Carter sold 3,000 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $75.20, for a total transaction of $225,600.00. Following the completion of the transaction, the director now directly owns 3,000 shares of the company’s stock, valued at $225,600. The disclosure for this sale can be found here. Over the last three months, insiders sold 40,041 shares of company stock valued at $2,895,485. 4.70% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC lifted its position in Mirati Therapeutics by 109.7% in the first quarter. FMR LLC now owns 4,606,270 shares of the biotechnology company’s stock worth $337,640,000 after buying an additional 2,409,882 shares during the last quarter. BlackRock Inc. lifted its position in Mirati Therapeutics by 30.0% in the fourth quarter. BlackRock Inc. now owns 2,052,949 shares of the biotechnology company’s stock worth $87,086,000 after buying an additional 474,097 shares during the last quarter. Janus Henderson Group PLC lifted its position in Mirati Therapeutics by 88.6% in the first quarter. Janus Henderson Group PLC now owns 2,034,744 shares of the biotechnology company’s stock worth $149,147,000 after buying an additional 956,022 shares during the last quarter. Jennison Associates LLC lifted its position in Mirati Therapeutics by 21.8% in the fourth quarter. Jennison Associates LLC now owns 1,216,464 shares of the biotechnology company’s stock worth $51,602,000 after buying an additional 217,960 shares during the last quarter. Finally, OppenheimerFunds Inc. lifted its position in Mirati Therapeutics by 0.4% in the first quarter. OppenheimerFunds Inc. now owns 819,956 shares of the biotechnology company’s stock worth $60,103,000 after buying an additional 3,146 shares during the last quarter.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.

Read More: Cryptocurrencies

Analyst Recommendations for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

William I. Jacobs Sells 600 Shares of Global Payments Inc  Stock
William I. Jacobs Sells 600 Shares of Global Payments Inc Stock
Stewart Butterfield Sells 2,500 Shares of Slack  Stock
Stewart Butterfield Sells 2,500 Shares of Slack Stock
Alice Lindsay Caulder Sells 501 Shares of World Acceptance Corp.  Stock
Alice Lindsay Caulder Sells 501 Shares of World Acceptance Corp. Stock
Insider Buying: ALS Ltd  Insider Buys 14,983 Shares of Stock
Insider Buying: ALS Ltd Insider Buys 14,983 Shares of Stock
Opko Health Inc.  CEO Purchases $106,000.00 in Stock
Opko Health Inc. CEO Purchases $106,000.00 in Stock
Robert Langer Sells 7,500 Shares of Rubius Therapeutics Inc  Stock
Robert Langer Sells 7,500 Shares of Rubius Therapeutics Inc Stock


© 2006-2019 Ticker Report